Shakti Press Ltd.

Feb 26, 2021 11:54 Source: BSE

Natco Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy

Feb 15, 2021 15:26 Source: BSE

Natco Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

copy of news paper publications

Feb 15, 2021 15:25 Source: BSE

Natco Pharma - Announcement under Regulation 30 (LODR)-Investor Presentation

Investor presentation for the quarter and nine months ended December 31, 2020

Feb 13, 2021 14:46 Source: BSE

Repro India - Announcement under Regulation 30 (LODR)-Newspaper Publication

We would like to inform you that we have published Un-Audited Financial Results for the third quarter and nine-months ended December 31, 2020, as approved by the Board of Directors of our Company in the following newspapers: 1. Business Standard (English) 2. Aapla Mahanagar (Marathi) We are enclosing the relevant paper cuttings of the above-mentioned newspapers for your reference and records.

Feb 12, 2021 17:20 Source: NSE

Repro India Limited

Repro India Limited has informed the Exchange about Investor Presentation

Feb 12, 2021 17:09 Source: BSE

Repro India - Announcement under Regulation 30 (LODR)-Investor Presentation

Dear Sir / Madam, Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the presentation to Analysts/Investors on Financial Results of the Company for the quarter and nine-months ended December 31, 2020. This is for your information and record.

Feb 12, 2021 17:06 Source: BSE

Repro India - Outcome Of Board Meeting

Dear Sir / Madam, The Board of Directors of the Company at their meeting held today i.e. February 12, 2021 has considered and approved the Un-Audited Financial Results (Standalone and Consolidated) for the third quarter and nine-months ended December 31, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Accordingly, please find enclosed Un-Audited Financial Results (Standalone and Consolidated) along with Limited Review Report of the Auditors. The meeting of the Board commenced at 3.00 p.m. and concluded at 4.45 p.m. This is for your information and records.

Feb 11, 2021 15:26 Source: BSE

Natco Pharma - Board declares Third Interim Dividend

Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2021, inter alia, has declared 3rd interim dividend of Rs. 1/- (Rupees one only) each per Equity share of Rs. 2/- (Rupees two only) each for the financial. year 2020-21 (which is 50% on the nominal value of the equity share).

Feb 11, 2021 15:03 Source: BSE

Natco Pharma - Record Date For Payment Of Interim Dividend

23rd February, 2021 fixed as Record Date for payment of Interim Dividend

Feb 11, 2021 14:48 Source: BSE

Natco Pharma - Un Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2020 Along With Press Release

Un audited Financial Results for the quarter and nine months ended 31st December, 2020 along with press release